Binimetinib (Standard)

CAT:
804-HY-15202R-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Binimetinib (Standard) - image 1

Binimetinib (Standard)

  • Description:

    Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
  • Product Name Alternative:

    MEK162 (Standard) ; ARRY-162 (Standard) ; ARRY-438162 (Standard)
  • UNSPSC:

    12352005
  • Hazard Statement:

    H411
  • Target:

    Autophagy; MEK; Reference Standards
  • Type:

    Reference Standards
  • Related Pathways:

    Autophagy; MAPK/ERK Pathway; Others
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/binimetinib-standard.html
  • Smiles:

    BrC1=CC=C(C(F)=C1)NC2=C(C3=C(C=C2C(NOCCO)=O)N(C=N3)C)F
  • Molecular Formula:

    C17H15BrF2N4O3
  • Molecular Weight:

    441.23
  • Precautions:

    P273-P391-P501
  • References & Citations:

    [1]J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.|[2]Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123 (6), 2551-2563.|[3]Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6 (39) :42183-96.|[4]Cheng H, et al. PIK3CA (H1047R) - and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35 (23) :2961-70.|[5]Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7 (15) :19997-20015.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Reference Standards
  • CAS Number:

    [606143-89-9]